|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM347146023 |
| 003 |
DE-627 |
| 005 |
20231226033142.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2022 xx |||||o 00| ||jpn c |
| 024 |
7 |
|
|a 10.14989/ActaUrolJap_68_9_291
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1157.xml
|
| 035 |
|
|
|a (DE-627)NLM347146023
|
| 035 |
|
|
|a (NLM)36199207
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Yoza, Naoto
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Early Experience with MRI-Ultrasound Fusion-Guided Prostate Biopsy in Our Institution
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 07.10.2022
|
| 500 |
|
|
|a Date Revised 11.10.2022
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a A total of 100 patients were retrospectively analyzed with magnetic resonance imaging-ultrasonography (MRI-US) fusion biopsy(KOELIS, TRINITY®) at our institution between October 2019 and May 2020. The median patient age was 71 years, median prostate specific antigen (PSA) level was 7.4 ng/ml, and median PSA-density was 0.183 mg/ml. Sixty-one of the patients were positive for cancer ; 14 of them were positive by targeted biopsy only, 9 were positive by systematic biopsy only, and 38 were positive by both. Clinically significant prostate cancer (CPSC ; Gleason Score ≥3＋4 and % core ≥50%) was detected by target biopsies in 46 patients and by systematic biopsies in 33 patients. The positive core detection rate for CSPC was 32.5% for targeted biopsies and 7.0% for systematic biopsies(P＜0.0001), with a significantly higher rate for targeted biopsies. These results indicate that in MRI-US fusion biopsy, targeted biopsy has a higher detection rate for cancer and a significantly higher detection rate for clinically significant prostate cancer compared with systematic biopsy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Prostate-Specific Antigen
|2 NLM
|
| 650 |
|
7 |
|a EC 3.4.21.77
|2 NLM
|
| 700 |
1 |
|
|a Nakazawa, Ryuto
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nishi, Tomohiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tsukada, Hikaru
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shirai, Daisuke
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Adachi, Hiroyuki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yamada, Ryuji
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Matsumura, Kaori
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Iwata, Teppei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Usuba, Wataru
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Aida, Kouichirou
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hayakawa, Nozomi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sasaki, Hideo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kikuchi, Eiji
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 68(2022), 9 vom: 01. Sept., Seite 291-294
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:68
|g year:2022
|g number:9
|g day:01
|g month:09
|g pages:291-294
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.14989/ActaUrolJap_68_9_291
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 68
|j 2022
|e 9
|b 01
|c 09
|h 291-294
|